| |
B/B a
|
B/T b
|
T/T c
|
|---|
| |
Full d
|
Outbreak-free e
|
Full
|
Outbreak-free
|
Full
|
Outbreak-free
|
|---|
| |
1-HR f
|
PH test g
|
1-HR
|
PH test
|
1-HR
|
PH test
|
1-HR
|
PH test
|
1-HR
|
PH test
|
1-HR
|
PH test
|
|---|
|
Vaccine efficacy
|
|
ages 1 to <5 years
|
0.45*
|
0.970
|
0.38
|
0.351
|
0.34
|
0.250
|
0.38
|
0.417
|
0.47*
|
0.931
|
0.44*
|
0.780
|
|
ages 5 to <15 years
|
0.67**
|
0.016
|
0.84**
|
0.617
|
0.71**
|
0.052
|
0.85**
|
0.806
|
0.59**
|
0.028
|
0.72**
|
0.217
|
|
ages 15 years and older
|
0.74**
|
0.008
|
0.69**
|
0.023
|
0.73**
|
0.025
|
0.69**
|
0.050
|
0.73**
|
0.058
|
0.71**
|
0.046
|
|
Participant age
|
|
1 to <5 years (ref)
|
0.0
| |
0.0
| |
0.0
| |
0.0
| |
0.0
| |
0.0
| |
|
5 to <15 years
|
0.69**
|
0.088
|
0.65**
|
0.011
|
0.74**
|
0.069
|
0.78**
|
0.249
|
0.77**
|
0.317
|
0.80**
|
0.542
|
|
15 years and older
|
0.81**
|
0.000
|
0.80**
|
0.000
|
0.88**
|
0.011
|
0.89**
|
0.043
|
0.89**
|
0.061
|
0.89**
|
0.095
|
|
Ward of residence
|
|
ward 29 (ref)
|
0.0
| |
0.0
| |
0.0
| |
0.0
| |
0.0
| |
0.0
| |
|
ward 30
|
0.40**
|
0.000
|
0.16
|
0.102
|
0.39**
|
0.000
|
0.15
|
0.209
|
0.39**
|
0.000
|
0.15
|
0.243
|
|
ward 33
|
0.07
|
0.979
|
-0.02
|
0.610
|
0.07
|
0.941
|
-0.01
|
0.719
|
0.07
|
0.755
|
-0.01
|
0.751
|
|
Large cluster
|
-0.61
|
0.382
|
-0.43
|
0.026
|
-0.60
|
0.403
|
-0.43
|
0.023
|
-0.60
|
0.384
|
-0.42
|
0.025
|
|
Own house
|
0.24
|
0.189
|
0.34*
|
0.549
|
0.24
|
0.351
|
0.34*
|
0.668
|
0.24
|
0.367
|
0.35*
|
0.715
|
|
Stable occupation
|
0.27
|
0.644
|
0.27
|
0.539
|
0.27
|
0.628
|
0.27
|
0.583
|
0.27
|
0.527
|
0.27
|
0.560
|
|
High income
|
0.32**
|
0.662
|
0.38**
|
0.125
|
0.32**
|
0.784
|
0.38**
|
0.109
|
0.32**
|
0.954
|
0.38**
|
0.121
|
|
Far from water
|
-0.31
|
0.013
|
-0.09
|
0.476
|
-0.31
|
0.025
|
-0.08
|
0.627
|
-0.31
|
0.044
|
-0.09
|
0.683
|
|
Global test h
| |
0.000
| |
0.003
| |
0.004
| |
0.312
| |
0.004
| |
0.233
|
|
Log lik ratio i
| | | |
106
| | | |
122
| | | |
118
|
- aboth vaccine and age effect are estimated for age group at baseline
- bvaccine effect is estimated for age group at baseline, age effect is estimated using time-dependent age groups
- cboth vaccine effect and age effect are estimated using time-dependent age groups
- dall participants were included
- eparticipants with events during March–April 2010 were excluded
- f1-hazard ratio, which can be interpreted as the protective efficacy for the vaccine effect. Significant terms (p< 0.05) are marked with * and highly significant terms (p< 0.01) are marked with **
- gp from test of proportional hazards (PH) assumption
- hglobal test of proportional hazards assumption
- ilog likelihood ratio relative to a Cox model with no covariate
